
TRML
Healthcare · Biotechnology · $1.23B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2025 | Time not confirmed | -0.91 | -0.90 | +1.1% |
| May 12, 2025 | Before the open | -0.94 | -0.89 | +4.9% |
| Mar 17, 2025 | Before the open | -0.87 | -0.86 | +1.1% |
| Nov 12, 2024 | After the close | -0.82 | -0.78 | +4.9% |
| Aug 8, 2024 | Before the open | -0.71 | -0.68 | +4.2% |
| May 13, 2024 | Before the open | -0.67 | -0.55 | +17.9% |
| Mar 19, 2024 | Before the open | -0.79 | -0.81 | -2.5% |
| Nov 14, 2023 | After the close | -0.60 | -1.64 | -173.7% |
| Aug 10, 2023 | Time not confirmed | -0.20 | -3.49 | -1647.3% |
| May 11, 2023 | Time not confirmed | -0.46 | -0.37 | +18.7% |
| Mar 16, 2023 | Time not confirmed | -0.49 | -5.20 | -961.2% |
| Nov 10, 2022 | Time not confirmed | -0.45 | -4.60 | -913.2% |
| Aug 15, 2022 | Time not confirmed | -0.46 |
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines…
| -4.40 |
| -867.0% |
| May 12, 2022 | Time not confirmed | -0.38 | -4.50 | -1074.0% |
| Mar 17, 2022 | Time not confirmed | -0.38 | -3.50 | -829.1% |
| Nov 12, 2021 | Time not confirmed | -0.35 | -3.20 | -814.3% |
| Aug 12, 2021 | Time not confirmed | -0.26 | -4.10 | -1476.9% |
| Jun 2, 2021 | Time not confirmed | -0.77 | -13.00 | -1581.1% |
| Mar 3, 2021 | Time not confirmed | — | -0.16 | — |